Skip to main content
Clinical Trials/NCT03809390
NCT03809390UnknownNot Applicable

Effects of Vaginal Seeding on Infants' Body Mass Index and Allergy Risk for Caesarean-delivered Children: A Randomized Controlled Study

Peking University1 site in 1 country117 target enrollmentStarted: November 17, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
117
Locations
1
Primary Endpoint
infant's body mass index

Study Overview

Brief Summary

This is a single-blind randomized controlled trial, aiming to evaluate the effects of vaginal seeding on body mass index as well as allergy risk for cesarean-delivered infants. It will be conducted in Liuyang city of China, and the targeted sample size is 106. All the eligible pregnant women will be randomly assigned to either the intervention or control group, and their babies of the participants will be followed up to 24 months of age.

Detailed Description

Many studies have suggested that caesarean-delivered children are at higher risks of developing metabolic and allergic diseases like obesity and asthma, possibly because newborns born by caesarean section were lack of exposure to maternal vaginal flora. It is needed to explore a simple, convenient, and safe intervention strategy to reduce caesarean-related risks. In a recent non-randomized study, the authors found that exposure of caesarean-delivered newborns to maternal vaginal fluid at birth (i.e., vaginal seeding) could partially restore the microbiota of them at 30 days after births, but the long-term health consequences of restoring the microbiota of caesarean-delivered infants remain unclear.

In this randomized study, the investigators aim to examine whether the changes in newborns' microbiota will persist to 24 month of age, and whether vaginal seeding will have any effects on body mass index and allergy risk from birth to 24 months of age. the investigators will enroll a total of 106 pregnant women, and the participants' infants will be followed up at 0 (before hospital discharge), 6, 12, 18 and 24 months. At each follow-up visit, a questionnaire survey including information on feeding, medication, and allergic status will be conducted, infants' height and weight will be measured, and feces will be collected. At 18-month-old visit, infants' venous blood will be also collected for the assay of multiallergen. The primary outcomes were body mass index and allergy risk index. The secondary outcomes included the microbiota profile, allergic symptoms and diseases, overweight/obesity, and adverse effects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • local resident in Liuyang city
  • Singleton, term pregnancy (≥37 weeks of gestation)
  • Cesarean section before labor starts without maternal complications, or cesarean section after the start of labor but the cervix is less than 3 cm
  • Vaginal pH< 4.5 at enrollment

Exclusion Criteria

  • Positive testing for HIV, HBV, syphilis or GBS infection at gestation
  • Vaginal infections such as genital herpetic lesions or chlamydia
  • Bacterial vaginosis
  • Trichomonas or fungous in leucorrhea
  • Pregnant women or her spouse with severe allergic diseases, such as asthma and severe drug allergy
  • Vaginal pH ≥4.5 at 1-2 hours before the cesarean section
  • Other conditions not suitable for intervention as judged by obstetricians

Outcomes

Primary Outcomes

infant's body mass index

Time Frame: At 24 months

Body mass index in original scale and z-score

infant's allergy risk score

Time Frame: At 18 months after birth

Calculated based on the measurements of multiallergens with 0-6 classes,higher values represent a worse outcome which means more susceptible to allergic diseases

Secondary Outcomes

  • Rate of allergic symptoms and common allergic diseases(At 61, 12 ,18 and 24 months)
  • Infants' gut microbiota profile(At baseline (Meconium), 6, 12 ,18 and 24 months after birth)
  • Rate of overweight/obesity(At 6, 12 ,18 and 24months)
  • Rate of adverse effects(From birth to 24 months)

Investigators

Sponsor
Peking University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jianmeng Liu

Professor in Perinatal Epidemiology

Peking University

Study Sites (1)

Loading locations...

Similar Trials